Health care systems across the globe rely on the advice and counsel of health care professionals (HCPs) when making decisions on new therapies to approve appropriate levels of reimbursement for various pharmaceutical products. These regulatory and reimbursement advisers have various backgrounds, including health outcomes and economics, clinical pharmacy and medicine.
Within each medical discipline, certain physicians regularly advise government regulatory agencies and public and private insurers on which therapies meet unmet medical demands and have the lowest risk for adverse reactions as well as provide input into reimbursement considerations. Each key opinion leader (KOL) assessment conducted by Thought Leader Select includes an examination of KOL engagement in regulatory and reimbursement activities.
In an ongoing assessment of nearly more than 150 HIV key opinion leaders across the globe, Thought Leader Select has analyzed their participation in regulatory and reimbursement activities. Using keywords to link these KOLs with such activities, Thought Leader Select found that 33% of physicians regularly provide input into regulatory and reimbursement decisions. The 53 KOLs with regulatory and reimbursement involvement are split nearly in half according to their participation in general or HIV-related activities (see Chart 1). However, the majority of Thought Leaders studied are involved in public reimbursement efforts (see Chart 2). Common regulatory and reimbursement groups among studied KOLs include:
• European Medicines Agency (EMEA).
• Agence Francaise de Securite Sanitaire des Produits de Sante (AFSSAPS).
• The London Consortium.
• Food and Drug Administration (FDA).
• Italian Medicines Agency (AIFA).
• British National Formulary.
• Brazilian Ministry of Health.
• Swedish Medical Products Agency (MPA).
• Spanish Ministry of Health and Consumption.